MX2016001220A - Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo. - Google Patents

Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.

Info

Publication number
MX2016001220A
MX2016001220A MX2016001220A MX2016001220A MX2016001220A MX 2016001220 A MX2016001220 A MX 2016001220A MX 2016001220 A MX2016001220 A MX 2016001220A MX 2016001220 A MX2016001220 A MX 2016001220A MX 2016001220 A MX2016001220 A MX 2016001220A
Authority
MX
Mexico
Prior art keywords
botulinum toxin
neurotoxic component
highly pure
preparing
pure neurotoxic
Prior art date
Application number
MX2016001220A
Other languages
English (en)
Inventor
Michael Pfeil
Andreas Wiesenburg
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2016001220A publication Critical patent/MX2016001220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un componente neurotóxico altamente puro de una toxina botulínica cultivando Clostridium botulinum bajo condiciones que permitan la producción de una toxina botulínica, y aislar el componente neurotóxico de la toxina botulínica. Además, la presente invención se refiere a un componente neurotóxico altamente puro de una toxina botulínica que se puede obtener mediante el procedimiento de la presente invención y usos del mismo.
MX2016001220A 2013-07-30 2014-07-30 Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo. MX2016001220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003792 2013-07-30
PCT/EP2014/002089 WO2015014487A1 (en) 2013-07-30 2014-07-30 Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof

Publications (1)

Publication Number Publication Date
MX2016001220A true MX2016001220A (es) 2016-05-24

Family

ID=48906087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001220A MX2016001220A (es) 2013-07-30 2014-07-30 Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.

Country Status (13)

Country Link
US (2) US9937245B2 (es)
EP (1) EP3027641A1 (es)
JP (1) JP6517800B2 (es)
KR (1) KR102272580B1 (es)
CN (1) CN105658662B (es)
AU (1) AU2014298922B2 (es)
BR (1) BR112016001730B1 (es)
CA (1) CA2918233C (es)
HK (1) HK1225744A1 (es)
IL (1) IL243573B (es)
MX (1) MX2016001220A (es)
RU (1) RU2663136C2 (es)
WO (1) WO2015014487A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP3027641A1 (en) * 2013-07-30 2016-06-08 Merz Pharma GmbH & Co. KGaA Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof
TWI669129B (zh) * 2014-12-23 2019-08-21 德商梅茲製藥有限兩合公司 預填充式玻璃容器及其套組與使用
EP3274044B1 (en) 2015-03-26 2023-03-01 Vensica Medical Ltd. Ultrasonic urinary bladder drug delivery
US11529506B2 (en) 2018-04-01 2022-12-20 Vensica Medical Ltd. System and method for ultrasonic bladder therapeutic agent delivery
JP6875318B2 (ja) * 2018-04-24 2021-05-19 株式会社日立産機システム 安全キャビネット

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
RU2206337C1 (ru) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US7339671B2 (en) * 2004-01-20 2008-03-04 Hong Peng Apparatus and method for monitoring biological cell culture
PL1891200T3 (pl) * 2005-06-17 2009-10-30 Merz Pharma Gmbh & Co Kgaa Urządzenie i sposób do fermentacyjnego wytwarzania biologicznie aktywnych materiałów
JP4944896B2 (ja) * 2005-11-17 2012-06-06 ルバンス セラピュティックス インク． 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8748151B2 (en) * 2008-08-29 2014-06-10 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
FR2981386B1 (fr) * 2011-10-14 2014-08-22 Getinge La Calhene Mecanisme de commande a haut niveau de securite pour un dispositif de transfert etanche entre deux volumes clos
EP3027641A1 (en) * 2013-07-30 2016-06-08 Merz Pharma GmbH & Co. KGaA Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof

Also Published As

Publication number Publication date
WO2015014487A1 (en) 2015-02-05
CA2918233A1 (en) 2015-02-05
JP2016527257A (ja) 2016-09-08
RU2663136C2 (ru) 2018-08-01
KR20160036581A (ko) 2016-04-04
EP3027641A1 (en) 2016-06-08
IL243573A0 (en) 2016-03-31
AU2014298922B2 (en) 2018-03-15
US20160175407A1 (en) 2016-06-23
BR112016001730B1 (pt) 2023-04-11
CN105658662B (zh) 2022-05-27
IL243573B (en) 2019-03-31
HK1225744A1 (zh) 2017-09-15
US9937245B2 (en) 2018-04-10
JP6517800B2 (ja) 2019-05-22
BR112016001730A2 (pt) 2017-08-29
AU2014298922A1 (en) 2016-02-18
CN105658662A (zh) 2016-06-08
US10653754B2 (en) 2020-05-19
RU2016103329A (ru) 2017-08-31
US20180147266A1 (en) 2018-05-31
CA2918233C (en) 2022-08-30
KR102272580B1 (ko) 2021-07-05

Similar Documents

Publication Publication Date Title
MX2016001220A (es) Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
MX2017010405A (es) Proceso y sistema para producir polipropiolactona.
MX2015016535A (es) Metodo de produccion para tagatosa.
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
PH12015500040B1 (en) Supercritical hydrolysis of biomass
PL2994229T3 (pl) Sposób wytwarzania 1,3-butadienu
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
MY182924A (en) Enzyme compositions and uses thereof
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
PH12018500150A1 (en) Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
PH12017501678A1 (en) Recombinant microorganism for improved production of finie chemicals
MX2015015148A (es) Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores.
MX362070B (es) Polioles que contienen tanino, su producción y su uso.
WO2014205355A3 (en) Compositions and methods for clostridial transformation
EP3103808A4 (en) Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
IN2013MU01113A (es)
MY175821A (en) Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same
MX2016013246A (es) Proceso para la produccion continua de polioles de polieter.
CO7141428A2 (es) Proceso para la elaboración de undecapéptidos cíclicos
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX2014013843A (es) Produccion de hidrofobina a partir de trichoderma.
EP4310503A3 (en) Methods related to biologics

Legal Events

Date Code Title Description
FG Grant or registration